bioAffinity Technologies reported record CyPath Lung testing volume in October 2026, the highest monthly volume for its noninvasive lung cancer test. Q3 CyPath Lung test unit sales rose 109% year to date over 2025, and ordering physicians increased 89%.
BIAF · bioAffinity Technologies, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“Based on our current expected level of operating expenditures, current expected levels of revenue, and the cash and cash equivalents on hand at September 30, 2026, of $2.6 million, management concludes that there is substantial doubt about our ability to continue as a going concern for a period of at least twelve (12) months subsequent to the issuance of the accompanying unaudited condensed consolidated financial statements contained in this Quarterly Report.”View the 10-Q filed Nov 6, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 28%
- Last earnings
- May 15, 2023
- Latest filing
- 10-Q · Nov 6
- Price history
- Sep 2022 to Nov 2026
Latest documents
bioAffinity Technologies reports a record 235 CyPath Lung tests performed in October 2026, up 29% from October 2025, its highest monthly testing volume. October volume was equivalent to approximately 45% of tests performed in Q3 2026.
bioAffinity Technologies reported that CyPath Lung test unit sales increased 100% through Q3 2026, while third-quarter revenue fell to approximately $1.1 million and net loss widened to approximately $5.3 million from approximately $5.1 million.
bioAffinity Technologies reported a net loss of $12.3 million for the nine months ended September 30, 2026, and management concluded there is substantial doubt about its ability to continue as a going concern. Cash and cash equivalents were $2.6 million at September 30, 2026, and $4.6 million as of November 3, 2026, which the company expects will support operations through March 2027.
bioAffinity Technologies will join physicians, patients and healthcare providers at the Lung Cancer Initiative of North Carolina's Battle of the Blues on November 5, 2026. It will share CyPath Lung, a noninvasive lung cancer test, at the event.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| awarded U.S. and foreign patents | 22 | now | — |
| clinical sites | 11 | As of September 30, 2026 | — |
| CyPath Lung testing revenue | $1.1M | first nine months of 2026 | — |
| number of ordering physicians | 89% | third quarter of 2026 | — |
| pending applications | 36 | now | — |
| Physicians already ordering CyPath Lung tests | 48% | third quarter of 2026 | — |
| CyPath Lung test reports delivered | 1,097 | Six months ended June 30, 2026 | — |
| CyPath® Lung diagnostic test volume | 216% | Q2 2026 | — |
| CyPath® Lung test results delivered | 622 | the three months ended June 30, 2026 filing | — |
| Existing client CyPath Lung orders | 71% | Six months ended June 30, 2026 | — |
| Physician offices and clinics ordering CyPath Lung | 122% | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BIAF
this stock
bioAffinity Technologies, Inc.
|
$3.37M | — | +14.5% | — | 2.9% |
|
TMO
Thermo Fisher Scientific Inc.
|
$255.19B | +18.9% | +14.5% | 36.3 | 1.3% |
|
DHR
Danaher Corp
|
$160.10B | -0.6% | +8.5% | 37.2 | 1.2% |
|
IDXX
Idexx Laboratories Inc
|
$54.33B | +1.9% | +10.4% | 46.5 | 3.0% |
|
A
Agilent Technologies, Inc.
|
$49.43B | +28.9% | +6.4% | 34.5 | 1.7% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 19, 2026
- This year
- 64
bioAffinity Technologies reported record CyPath Lung testing volume in October 2026, the highest monthly volume for its noninvasive lung cancer test. Q3 CyPath Lung test unit sales rose 109% year to date over 2025, and ordering physicians increased 89%.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BIAF | -20.9% | -41.6% | -93.0% | -36.4% | -89.6% |
| SPY | -5.5% | -6.3% | -5.6% | -5.3% | +5.0% |
| vs SPY | -15.5% | -35.4% | -87.3% | -31.2% | -94.5% |